Kate Broderick, PhD

Chief Innovation Officer

Dr. Kate Broderick leverages more than 20 years of life science experience with over 15 years in research and development as the head of Maravai’s newly established Science and Innovation Office. A recognized expert in vaccine and nucleic acid technology, Dr. Broderick has led global teams and collaborated with industry, academic, and government partners to develop vaccines for a wide range of infectious diseases, including Ebola, MERS, Zika, HIV, Lassa fever, and COVID-19. Before joining Maravai in 2022, Dr. Broderick held roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President of R&D Dr. Broderick received her PhD from the University of Glasgow in Scotland and completed post-doctoral research at the University of California, San Diego.